Metabolic Enzyme/Protease Neuronal Signaling Anti-infection Cell Cycle/DNA Damage MAPK/ERK Pathway TGF-beta/Smad Stem Cell/Wnt Apoptosis NF-κB Immunology/Inflammation Epigenetics PI3K/Akt/mTOR
Tyrosinase Phosphatase Cholinesterase (ChE) SARS-CoV PERK JNK p38 MAPK TGF-beta/Smad Apoptosis Reactive Oxygen Species (ROS) AMPK MMP
Methyl rosmarinate

Cat. No.: HY-N3266

Methyl rosmarinate

Customer Review

Based on 1 Customer Validation

Methyl rosmarinate is an orally active hydroxycinnamic acid. Methyl rosmarinate exhibits an IC₅₀ of 24.70 μM and a K_i of 15.29 μM against PTP1B, an IC₅₀ of 41.46 μg/mL against BChE, a K_i of 0.61 mM against mushroom tyrosinase, and an IC₅₀ of 2.50 μM against SARS-CoV-2 3CLpro. Methyl rosmarinate downregulates the phosphorylation levels of ERK, JNK, p38, Smad2 and Smad3. Methyl rosmarinate activates erythrocyte BPGM and promotes the production of 2,3-BPG. Methyl rosmarinate induces apoptosis of fibroblasts. Methyl rosmarinate prolongs the survival time of hypoxic mice. Methyl rosmarinate improves insulin sensitivity. Methyl rosmarinate binds to SARS-CoV-2 3CLpro and inhibits viral replication. Methyl rosmarinate induces glioblastoma cell death. Methyl rosmarinate activates the TGR5/AMPK axis and reduces the levels of ROS and MDA. Methyl rosmarinate shows inhibitory activity against MMP-1. Methyl rosmarinate can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, COVID-19, glioblastoma and myocardial ischemia-reperfusion injury.

For research use only. We do not sell to patients.

Purity: 99.46%
CAS No.: 99353-00-1
Formula: C₁₉H₁₈O₈
Molecular Weight:374.34

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Methyl rosmarinate Chemical Structure

CAS No.: 99353-00-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 0.28 mM (mushroom tyrosinase), a -glucosidase^[1]

All Cholinesterase (ChE) Isoforms :

AChE
BChE

All JNK Isoforms :

All p38 MAPK Isoforms :

All TGF-beta/Smad Isoforms :

Smad1
Smad3

All AMPK Isoforms :

All MMP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MOLM-13	IC₅₀	8.4 μM Compound: 20	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	>10 μM Compound: 20	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MV4-11	IC₅₀	>10 μM Compound: 20	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
RAW264.7	IC₅₀	11.3 μM Compound: 26	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
Vero C1008	CC₅₀	>1000 μM Compound: 4	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37267066]

In Vitro

Methyl rosmarinate (10-160 μM; 48 h) exhibits cytotoxicity against L929 cells, with an IC₅₀ of 76.27 μM^[1].
Methyl rosmarinate (10-40 μM; 48 h) reduces extracellular matrix protein accumulation in TGF-β1-stimulated L929 cells^[1].
Methyl rosmarinate (20-40 μM; 12-72 h) inhibits the proliferation and migration of TGF-β1-stimulated mouse fibroblast L929 cells and increases the cellular apoptosis rate^[1].
Methyl rosmarinate (20-40 μM; 48 h) upregulates the expression levels of pro-apoptotic proteins Bax, cleaved caspase 3, and cleaved caspase 9, downregulates the expression level of anti-apoptotic protein Bcl-2, inhibits the phosphorylation of TGF-β1/Smad and MAPK signaling pathways, and alleviates the fibrotic response in TGF-β1-stimulated mouse fibroblast L929 cells^[1].
Methyl rosmarinate competitively and reversibly inhibits the activity of recombinant human PTP1B enzyme, with an IC₅₀ of 24.7 μM and a K_i of 15.29 μM^[3].
Methyl rosmarinate (6.25-25 μM; 24 h) acts as an insulin sensitizer, enhancing insulin-stimulated glucose uptake and glycogen synthesis in fully differentiated C2C12 myotubes. It activates the insulin signaling pathway and increases insulin-stimulated phosphorylation levels of IRS-1 and Akt, without altering the protein expression level of PTP1B^[3].
Methyl rosmarinate inhibits butyrylcholinesterase (BChE) with an IC₅₀ of 41.46 µg/mL, but exerts no significant inhibitory effect on acetylcholinesterase (AChE)^[4].
Methyl rosmarinate (0.01-0.4 mM; 2 min preincubation, 5 min reaction) inhibits the diphenolase activity of mushroom tyrosinase with a K_i of 0.61 mM, and inhibits yeast α-glucosidase activity^[5].
Methyl rosmarinate acts as an allosteric inhibitor of purified SARS-CoV-2 3CLpro, with an IC₅₀ of 2.5 μM, a K_i of 1.27 μM, and a K_d of 5.93 μM^[6].
Methyl rosmarinate (1-200 μM; 52 h total) inhibits the replication of SARS-CoV-2 replicons in Huh7 cells, with an EC₅₀ of 18.91 μM, and only exhibits moderate cytotoxicity at the concentration of 200 μM^[6].
Methyl rosmarinate (5-60 μM; 72 h) reduces the viability of human glioblastoma U87 (IC₅₀ = 9.8 μM) and T98 (IC₅₀ = 13 μM) cell lines in a dose-dependent manner^[7].
Methyl rosmarinate (9.8-19.6 μM in U87 cells; 13-26 μM in T98 cells; 72 h) induces subG0 and S phase arrest in U87 cells, and subG0 and G2/M phase arrest in T98 cells^[7].
Methyl rosmarinate (9.8-19.6 μM in U87 cells; 13-26 μM in T98 cells; 48 h) inhibits the migration of U87 and T98 cell lines in a dose-dependent manner^[7].
Methyl rosmarinate inhibits purified human MMP-1 with an IC₅₀ of 14.7 μM^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

mouse fibroblast L929 cells
Concentration:

0, 10, 20, 40, 80, and 160 μM
Incubation Time:

48 h
Result:

Exhibited cytotoxicity toward L929 cells, with an IC₅₀ value of 76.27 μM.
Reduced cell viability to 92.53% of the control at 80 μM.
Reduced cell viability to 48.82% of the control at 160 μM.

Western Blot Analysis^[1]

Cell Line:

TGF-β1-stimulated mouse fibroblast L929 cells
Concentration:

10, 20, 40 μM
Incubation Time:

48 h (following 72 h of TGF-β1 stimulation)
Result:

Dose-dependently reduced the elevated expression of collagen-I, collagen-III, vimentin, α-SMA, and snail proteins induced by TGF-β1 stimulation.
Caused significant, concentration-dependent decreases in the expression of all these fibrosis-associated proteins relative to TGF-β1-only treated cells.

Cell Proliferation Assay^[1]

Cell Line:

TGF-β1-stimulated mouse fibroblast L929 cells
Concentration:

20, 40 μM
Incubation Time:

12, 24, 48, 72 h (co-treated with TGF-β1)
Result:

Significantly inhibited the increased proliferation of L929 cells induced by TGF-β1 at all measured time points.
Showed statistically significant inhibitory effects at both 20 μM and 40 μM concentrations relative to TGF-β1-only treated cells.

Cell Migration Assay ^[1]

Cell Line:

TGF-β1-stimulated mouse fibroblast L929 cells
Concentration:

20, 40 μM
Incubation Time:

24, 48 h (following TGF-β1 induction)
Result:

Significantly reduced the migration rate of TGF-β1-stimulated L929 cells at both 24 and 48 h.
Showed a stronger inhibitory effect at 40 μM concentration relative to the 20 μM concentration.

Apoptosis Analysis^[1]

Cell Line:

TGF-β1-stimulated mouse fibroblast L929 cells
Concentration:

20, 40 μM
Incubation Time:

48 h (following TGF-β1 induction)
Result:

Significantly increased the apoptosis rate of TGF-β1-stimulated L929 cells.
Increased apoptosis rate to 5.49% at 20 μM relative to 3.53% in TGF-β1-only treated cells.
Increased apoptosis rate to 10.32% at 40 μM relative to 3.53% in TGF-β1-only treated cells.

Western Blot Analysis^[1]

Cell Line:

TGF-β1-stimulated mouse fibroblast L929 cells
Concentration:

20, 40 μM
Incubation Time:

48 h (following TGF-β1 induction)
Result:

Increased expression of pro-apoptotic proteins Bax, cleaved caspase 3, and cleaved caspase 9 in a dose-dependent manner relative to TGF-β1-only treated cells.
Decreased expression of anti-apoptotic protein Bcl-2 in a dose-dependent manner relative to TGF-β1-only treated cells.\nDose-dependently reduced the phosphorylation ratios of p-Smad2/Smad2, p-Smad3/Smad3, p-ERK/ERK, p-JNK/JNK, and p-p38/p38 in TGF-β1-stimulated L929 cells.
Caused statistically significant decreases in phosphorylation ratios at both 20 and 40 μM relative to TGF-β1-only treated cells.

Western Blot Analysis^[3]

Cell Line:

fully differentiated C2C12 myotubes
Concentration:

6.25, 12.5 and 25 μM
Incubation Time:

24 h
Result:

Did not alter PTP1B protein expression.
Dose-dependently enhanced insulin-stimulated phosphorylation of IRS-1 and Akt, with significant increases observed at 12.5 and 25 μM relative to the insulin-only group.

Cell Viability Assay^[7]

Cell Line:

human glioblastoma U87, T98 cell lines
Concentration:

5, 15, 30, 45, 60 μM
Incubation Time:

72 h
Result:

Reduced cell viability in a dose-dependent manner in both cell lines.
Reached a half maximal inhibitory concentration (IC₅₀) of 9.8 μM in U87 cells and 13 μM in T98 cells.
Induced morphological changes including shrinking and death at higher concentrations.

Cell Cycle Analysis^[7]

Cell Line:

human glioblastoma U87, T98 cell lines
Concentration:

9.8, 19.6 μM (U87 cells); 13, 26 μM (T98 cells)
Incubation Time:

72 h
Result:

Increased subG0/G1 phase from 1.9945% to 16.331% and S phase from 7.318% to 15.249% in U87 cells.
Increased subG0/G1 phase from 0.835% to 5.179% and G2/M phase from 4.502 to 16.551 in T98 cells.
Caused statistically significant changes in both cell lines.

In Vivo

Methyl rosmarinate (20 mg/kg; p.o.; daily; from day 3 to day 28) significantly attenuates Bleomycin (HY-108345)-induced pulmonary fibrosis in male C57BL/6 mice^[1].
Methyl rosmarinate (25-75 mg/kg, i.p.; once daily for 3 consecutive days) prolongs the survival time of mice under normobaric closed hypoxia. It protects mice from damage caused by high-altitude field hypoxia by reducing inflammatory factors, improving tissue oxidative stress, alleviating tissue pathological damage and relieving tissue hypoxia. Additionally, it enhances the glycolysis pathway activity of red blood cells in Mus musculus exposed to high-altitude field hypoxia, activates BPGM, and increases the level of 2,3-BPG, thereby improving the oxygen release capacity of red blood cells^[2].
Methyl rosmarinate (6.25-25 mg/kg; oral gavage; daily; 7 weeks) improves insulin sensitivity, restores glucose and lipid homeostasis, protects skeletal muscle and organ function, and enhances β-cell function in type 2 diabetic mice induced by high-fat diet/Streptozotocin (HY-13753)^[3].
Methyl rosmarinate (50-200 mg/kg; i.p.; single administration 3 hours before ligation) dose-dependently improves cardiac function, and alleviates myocardial injury, oxidative stress and mitochondrial damage in Mus musculus (mouse) models of myocardial ischemia-reperfusion injury by activating the TGR5/AMPK signaling axis^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, bleomycin-induced pulmonary fibrosis model)^[1]
Dosage:

20 mg/kg
Administration:

p.o.; daily; day 3 to day 28
Result:

Significantly improved mouse body weight and reduced lung fibrosis as visualized by small animal MicroCT.
Improved lung structure, reduced inflammatory cell infiltration, and decreased collagen deposition compared to the bleomycin-only group.
Reduced Ashcroft fibrosis score from ~5.2 in the bleomycin-only group to ~1.8.
Reduced collagen deposition area from ~50% in the bleomycin-only group to ~45%.
Significantly reduced lung tissue levels of fibrosis-associated proteins collagen-I and collagen-III compared to the bleomycin-only group.

Animal Model:

BALB/c (male and female, 18-22 g)^[2]
Dosage:

25 mg/kg; 50 mg/kg; 75 mg/kg
Administration:

i.p.; daily; 3 days
Result:

Prolonged survival time by 20.15% (31.89 minutes) at 25 mg/kg vs.
blank control.
Prolonged survival time by 24.35% (33.00 minutes) at 50 mg/kg vs.
blank control.
Prolonged survival time by 24.19% (32.96 minutes) at 75 mg/kg vs.
blank control.
Showed statistically significant survival time increases across all dose groups vs.
blank control.

Animal Model:

C57BL/6 J (male, 6 weeks old, high-fat diet + streptozotocin-induced type 2 diabetes)^[3]
Dosage:

6.25 mg/kg; 25 mg/kg
Administration:

i.g.; daily; 7 weeks
Result:

Reversed decreased body weight and elevated fasting blood glucose levels, with effects comparable to metformin.
Reduced weekly food intake and decreased glycosylated serum protein (GSP) levels in a dose-dependent manner.
Improved glucose clearance during GTT and insulin sensitivity during ITT, as evidenced by reduced area under the curve (AUC) values compared to vehicle-treated T2D mice.
Increased fasting serum insulin (FINS) levels; the 25 mg/kg dose significantly reduced the homeostasis model assessment of insulin resistance (HOMA-IR) index and improved the homeostasis model assessment of β-cell function (HOMA-β) index.
Improved lipid profiles by reducing total cholesterol (T-CHO), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
Reversed T2D-induced loss of skeletal muscle mass (improved indexes of extensor digitorum longus, tibialis anterior, soleus, gastrocnemius, and quadriceps muscles) and protected against skeletal muscle fiber atrophy.
Elevated glycogen synthesis in skeletal muscle, restored insulin-stimulated phosphorylation of IRS-1 and Akt in skeletal muscle, and downregulated PTP1B protein expression in skeletal muscle (the 25 mg/kg dose returned PTP1B expression to normal levels).
The 25 mg/kg dose reduced liver and kidney indexes, attenuated liver steatosis and renal tubule vacuolation, and decreased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, with no observed toxicity in normal mice.

Animal Model:

C57BL/6 J (male, 6-8 weeks old, 20-22 g, myocardial ischemia-reperfusion injury model via left anterior descending coronary artery ligation for 30 minutes followed by reperfusion; some groups received tail vein injection of AV-TGR5, AV-sh-TGR5, or negative control AAV9 3 weeks prior to injury)^[8]
Dosage:

50 mg/kg; 100 mg/kg; 200 mg/kg
Administration:

i.p.; single dose 3 h pre-ligation
Result:

Increased LVDP, +dp/dtmax, and −dp/dtmax, and decreased LVEDP dose-dependently compared to MIRI controls.
Reduced serum CK-MB and LDH levels, and reduced myocardial infarct size dose-dependently compared to MIRI controls.
Preserved myocardial fiber structure, reduced inflammatory cell infiltration, hemorrhage, edema, and necrosis; reduced myocardial fibrosis area and cardiomyocyte apoptosis rate dose-dependently compared to MIRI controls.
Reduced cleaved caspase 3 and Bax protein levels, and increased Bcl-2 protein levels compared to MIRI controls.
Reduced myocardial ROS, serum MDA, and serum LPO levels, and increased serum SOD levels dose-dependently compared to MIRI controls.
Reduced mitochondrial damage rate, improved mitochondrial structure, and reduced mitochondrial swelling and vacuolar degeneration dose-dependently compared to MIRI controls.
Increased myocardial TGR5 and p-AMPK protein levels dose-dependently compared to MIRI controls.
When combined with 100 mg/kg methyl rosmarinate, TGR5 overexpression further enhanced cardiac function, reduced myocardial injury markers, infarct size, pathological damage, oxidative stress, and mitochondrial damage, and further increased TGR5 and p-AMPK levels compared to methyl rosmarinate alone.
TGR5 knockdown reversed the beneficial effects of methyl rosmarinate, reducing cardiac function, increasing injury markers, pathological damage, oxidative stress, and mitochondrial damage, and decreasing TGR5 and p-AMPK levels compared to methyl rosmarinate alone.

Chemical Information

CAS No. 99353-00-1
Appearance Solid
Molecular Weight 374.34
Formula C₁₉H₁₈O₈
Color White to light yellow
SMILES

OC1=C(O)C=CC(/C=C/C(O[C@@H](C(OC)=O)CC2=CC(O)=C(O)C=C2)=O)=C1
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (267.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6714 mL

13.3568 mL

26.7137 mL

5 mM

0.5343 mL

2.6714 mL

5.3427 mL

10 mM

0.2671 mL

1.3357 mL

2.6714 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (300 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ma L, et al. (2024) Anti-pulmonary fibrosis activity analysis of methyl rosmarinate obtained from Salvia castanea Diels f. tomentosa Stib. using a scalable process. Front. Pharmacol. 15:1374669.

[2]. Guo Q, et al. Study on the Protective Effect of Methyl Rosmarinate on Hypoxic Mice and Their Erythrocytes. Drug Des Devel Ther. 2025;19:3179-3192. Published 2025 Apr 24. [Content Brief]

[3]. Xie B, et al. Bioactivity-based molecular networking-guided identification of methyl rosmarinate from Orthosiphon aristatus as a PTP1B inhibitor that improves insulin sensitivity in diabetic mice. Phytomedicine. 2025;148:157444. [Content Brief]

[4]. Senol Deniz FS, et al. Outlining In Vitro and In Silico Cholinesterase Inhibitory Activity of Twenty-Four Natural Products of Various Chemical Classes: Smilagenin, Kokusaginine, and Methyl Rosmarinate as Emboldening Inhibitors. Molecules. 2021;26(7):2024. Published 2021 Apr 1. [Content Brief]

[5]. Lin L, et al. Comparative evaluation of rosmarinic acid, methyl rosmarinate and pedalitin isolated from Rabdosia serra (MAXIM.) HARA as inhibitors of tyrosinase and α-glucosidase. Food Chem. 2011;129(3):884-889. [Content Brief]

[6]. Li H, et al. Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection. Antiviral Res. 2024;224:105841. [Content Brief]

[7]. Benekou MV, et al.Antineoplastic Activity of Methyl rosmarinate in Glioblastoma Cells. Curr Issues Mol Biol. 2025 Mar 10;47(3):180. [Content Brief]

[8]. Zhou W, et al. Methyl rosmarinate alleviates myocardial ischemia-reperfusion injury in mice via triggering TGR5/AMPK signaling axis. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(4):5267-5284. [Content Brief]

[9]. Yuan H, et al. Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). Eur J Med Chem. 2013;62:148-157. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6714 mL	13.3568 mL	26.7137 mL	66.7842 mL
	5 mM	0.5343 mL	2.6714 mL	5.3427 mL	13.3568 mL
	10 mM	0.2671 mL	1.3357 mL	2.6714 mL	6.6784 mL
	15 mM	0.1781 mL	0.8905 mL	1.7809 mL	4.4523 mL
	20 mM	0.1336 mL	0.6678 mL	1.3357 mL	3.3392 mL
	25 mM	0.1069 mL	0.5343 mL	1.0685 mL	2.6714 mL
	30 mM	0.0890 mL	0.4452 mL	0.8905 mL	2.2261 mL
	40 mM	0.0668 mL	0.3339 mL	0.6678 mL	1.6696 mL
	50 mM	0.0534 mL	0.2671 mL	0.5343 mL	1.3357 mL
	60 mM	0.0445 mL	0.2226 mL	0.4452 mL	1.1131 mL
	80 mM	0.0334 mL	0.1670 mL	0.3339 mL	0.8348 mL
	100 mM	0.0267 mL	0.1336 mL	0.2671 mL	0.6678 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Methyl rosmarinate

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Phosphatase Inhibitor Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library